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Background: The clinical characteristics of children diagnosed with Rett syndrome are well described. Survival and
how these characteristics persist or change in adulthood are less well documented. This study aimed to describe
overall survival and adult health in those with Rett syndrome.
Methods: Using the Kaplan-Meier method, we estimated survival of individuals registered with the Australian Rett
syndrome Database (ARSD) who had been followed for up to 20 years (n = 396). We then conducted logistic and
linear regression analyses investigating epilepsy, musculoskeletal, gastrointestinal, autonomic dysfunction and
behaviour of individuals aged 18 years and over using cross sectional cohorts from the ARSD (n = 150) and the
international database InterRett (n = 273).
Results: The likelihood of survival was 77.6% at 20 years, 71.5% at 25 years and 59.8% at 37 years. The median age
of the combined cross-sectional cohort was 25 years (range 18 to 54 years), the majority (71%) were living in their
parental home and the remainder being cared for in group homes or other institutions. Just over half walked either
independently (18%) or with assistance (43%). The majority (86%) had scoliosis with 40% of those having undergone
corrective surgery. Almost two-thirds (64%) of the women were taking anti-epileptic medications at the time of
data collection. Constipation was highly prevalent (83%) and many experienced bloating (53%). Biliary dyskinesia,
inflammation or infection of the gallbladder was reported for 20 women (5%) and of those 13 had undergone
gallbladder surgery. Sleep disturbance was relatively common (63%), and adverse mood events and anxiety were
slightly more prevalent in those aged 26-30 years in comparison to the younger and older age groups. Other
frequently reported medical conditions included urinary tract infections, pneumonia and other respiratory conditions.
Conclusions: Survival in Rett syndrome has now been estimated with the most accurate follow up to date. During
adulthood, continuation of multidisciplinary services and programs is necessary to optimise health and wellbeing.
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The neurological disorder Rett syndrome (OMIM 312750)
was first described in the English literature in 1983 [1] and
later found to be associated with mutations in the methyl
CpG binding protein 2 gene (MECP2) [2]. Females are
mostly affected with an incidence of diagnosis of 1:9000
by the age of 32 years [3]. Diagnosis depends on clinical
presentation [4] with or without a pathogenic MECP2
mutation. Genetic testing occurs commonly in current
diagnostic pathways but many older women may not have
undergone genetic testing. The clinical characteristics of* Correspondence: helen.leonard@telethonkids.org.au
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unless otherwise stated.Rett syndrome first appear in early childhood. Gradual or
sudden loss of speech and hand function, loss of acquired
gross motor skills and the development of stereotypic
hand movements mark a period of regression between the
ages of 6 and 18 months. Gastrointestinal problems, re-
spiratory dysfunction such as hyperventilation, breath
holding and apnoea, sleep disturbance, spinal curvature
and epilepsy are common comorbidities. Overall severity
of symptoms is highly variable across individuals and stud-
ies have identified common mutations associated with
either a milder phenotype (point mutations p.Arg133Cys,
p.Arg294*, and p.Arg306Cys) or a more severe clinical
presentation (point mutations p.Thr158Met, p.Arg168*,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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presentation in adults with Rett syndrome is less well
understood.Emerging picture of health and wellbeing in adults with
Rett syndrome
Thus far only two studies conducted in the Netherlands
(2007: n = 53, 2012: n = 37) [7] and Italy (n = 84) [8] have
specifically examined health in adults with Rett syn-
drome. Overall, general health was reported to be good.
However epilepsy was found to be highly prevalent in
both the Dutch (93%) and the Italian cohorts (82%), and
while improvement in seizure activity with age was noted
for some women [8], some remained difficult to treat and
the majority required medications for control of seizures.
A post-adolescence decline in gross motor skills has been
reported in some [7,9] but not all women with Rett
syndrome [7]. Gross motor capabilities are influenced by
the type of mutation present in the MECP2 gene and are
generally poorer in those requiring surgical correction for
scoliosis [10]. Autonomic dysfunction which may manifest
as hyperventilation or breath holding, or peripheral vaso-
motor disturbances is a well-recognised but poorly under-
stood feature of Rett syndrome. Abnormal or disturbed
sleep patterns and behavioural issues also appeared to
persist [7,8]. Similarly, gastrointestinal issues such as con-
stipation, reflux, and feeding difficulties remained pre-
valent [7,8] and may contribute to poor growth [11].
However, there is a need for replication of these studies
using larger sample sizes to improve our understanding of
clinical presentations beyond the growth and development
of childhood.Survival
It is possible that those adults with Rett syndrome who
survive into adulthood may represent a healthier group.
The most recent Australian population-based estimate
indicated that ~70% would be alive at 25 years with
some evidence of improved survival over calendar time
when comparing with the historical Austrian cohort
[12]. A study using data on 1,907 cases ascertained from
a combined US and Canadian sample (n = 2,994) showed
a similar result at age 25 years [13]. A recent longitu-
dinal study conducted in The Netherlands [7] reported
the death of 7 of 53 women aged between 21 and 43
years over a five-year period. However, it is difficult to
measure survival accurately using small samples that are
not population-based with only short follow-up time.
Our aims were to update our previous estimate of sur-
vival with now 20 years of follow-up in the Australian
Rett Syndrome Database (ARSD) and to describe health
status in individuals aged 18 years or older sourced from
both the ARSD and the InterRett database.Methods
Data sources
Data for this study were harnessed from two data reposi-
tories: The ARSD and the international database InterRett.
The ARSD is a population-based registry established in
1993 [14] representing individuals born since 1976. Ques-
tionnaires are administered on enrolment to both families
and clinicians and subsequently, follow-up questionnaires
are administered approximately biennially to families. The
InterRett database was first established in 2002 and invites
participation from both families and clinicians on a global
level [15]. Families who register are administered a family
questionnaire and one of the clinicians caring for their
family member with Rett syndrome is also invited to
complete a clinician questionnaire. Ethics approval for
both studies was obtained from the Princess Margaret
Hospital for Children, Western Australia.
Survival
Female cases with a confirmed diagnosis of Rett syndrome
registered with the ARSD (n = 396) were included. Data
on deceased status and cause of death (excluding cases
that were subject to a coroner’s investigation) were ob-
tained from the Australian Institute of Health and Welfare
(AIHW) National Death Index (NDI) database and were
valid as at 31st January 2014. Age at first contact with the
ARSD was used as entry points and age at death or age at
last contact date if alive was used as exit points. Time as
risk was defined as the difference between the entry and
exit points, reflecting the delayed entry nature of the
study. As such, the interpretation of the survival time is
that of survival to exit age conditional on survival up to
the age at entry. The censor status of each case was set as
1 if the individual was deceased and 0 if the individual was
known to be alive.
Health status
Females aged 18 years or older at their most recent data
collection were sourced from both the ARSD (n = 150)
and InterRett (n = 273) databases providing a total of 423
unique cases. Rett syndrome diagnosis was confirmed
at ascertainment based on consensus diagnostic criteria
[4,16,17] or on the presence of a pathogenic mutation in
the MECP2 gene.
Demographic information and variables relevant to
health status that had been harmoniously ascertained
across the two databases were selected for analysis. Clin-
ical comorbidities included epilepsy, musculoskeletal as-
pects (mobility, scoliosis), gastrointestinal health (weight,
constipation, reflux, bloating and gall bladder problems),
autonomic dysfunction, sleep disturbance, and mood and
anxiety. Where more detailed information on a particular
health area was available in one data source but not the
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Figure 1 Kaplan Meier survival curve for 396 girls and women
with Rett syndrome.
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to describe any medical problems (current or present)
other than those usually associated with Rett syndrome or
that had required day admissions or surgery in hospital.
This information was reviewed to determine whether
or not any particular medical problems were more
represented.
Ability to walk was categorised as one of the following:
no assistance required, a little assistance (eg, one hand
held), a moderate amount of assistance (eg, needing trunk
support) or unable to walk. Epilepsy status was categorised
according to frequency of seizures and the number of
anti-epileptic medications. Active epilepsy represents
those with seizure frequency of at least monthly at
the time the questionnaire was completed, and drug re-
sistant epilepsy was defined as having active epilepsy and
taking two or more anti-epileptic drugs at the time of data
collection [18].
Responses to the Rett Syndrome Behaviour Question-
naire (RSBQ) [19], which has been administered for the
Australian cohort, were used to calculate scores for the
mood and anxiety subscales. The mood subscale com-
prised eight questions describing behaviours such as
screaming spells and irritability with 3 response options
(0-2) giving a possible total score of 16. The anxiety
subscale score comprised four questions describing behav-
iours such as panic spells and fear with 3 options (0-2)
giving a possible total score of 8. Higher scores indicated
more problematic behaviours.
Also for the Australian cohort, weight z-scores for age
were calculated using the LMS method based on data
from the 2000 US Centers for Disease Control and Pre-
vention Growth [20]. The reference value of age 20 years
was applied to any individual over this age.
Mutations were grouped as large deletions (LD), C-
terminal deletions (CT), early truncating (ET) or one of
the common eight mutations. All others were grouped
as “other” mutations. Females who were mutation negative
or with unknown mutation status were included in the
“Negative/Unknown” (Neg/Unk) group. Age was grouped
as 25 years and younger, between 26 and 30 years, and
older than 30 years for health status comparisons.
Statistical analysis
The Kaplan-Meier method was used for estimating the
conditional probability of survival. Cox proportional
hazards models were fitted to investigate the influence
of genotype on survival and logistic regression was used
to estimate the associations of mutation type and age
with the presence of comorbidity. The p.Arg133Cys
group, a mutation associated with an overall milder phe-
notype [21], was used as a baseline. The effects of muta-
tion type on continuous independent variables such as
weight, RSBQ mood score and RSBQ anxiety score wereassessed using simple linear regression. Predicted values
of these explanatory variables were then estimated based
on the recycled predictions approach using the Stata
margins command.
All statistical analyses were conducted using Stata soft-
ware version 13 [22].
Results
Survival
As in January 2014 the ARSD contained birth and death
information for 396 females (median age 18.3, inter-
quartile range (IQR) 12.1-25.4 years). Information on cause
of death was available for 57 (82.6%) out of 69 females who
were deceased. Lower respiratory tract infection (36.8%
21/57) was the most common cause of death, followed by
aspiration/asphyxiation (31.6% 18/57), respiratory failure
(14.0% 8/57) and seizure related illness (5.3% 3/57). The
conditional probability of survival was 77.6% (95% confi-
dence interval (CI) 71.3, 82.8) at 20 years, 71.5% (95% CI
64.6, 77.3) at 25 years and 59.8% (95% CI 49.3,68.8) at 37
years (Figure 1). There were 300 females in the ARSD
with a pathogenic mutation in the MECP2 gene (Table 1)
and 96 females with negative MECP2 testing or unknown
genotype. Using the Cox proportional hazard model, those
with large deletions had, at any time during the obser-
vation period, slightly more than 3 times (HR 3.11, 95% CI
0.60, 16.10) the risk of death than those with the
p.Arg133Cys mutation. High mortality risk was also ob-
served in those with p.Arg270* (HR 3.05, 95% CI 0.63,
14.73), p.Arg106Trp (HR 2.24, 95% CI 0.45, 11.11)
and p.Arg306Cys mutations (HR 2.66, 95% CI 0.49, 14.53)
(Figure 2). The risk was lowest for those with the
p.Arg255* mutation (HR 0.52, 95% CI 0.05, 5.76).
Health status
The combined study population represented 24 countries
with the greatest numbers residing in the USA (40.4%,
Table 1 Number (%) of girls and women in the survival
analysis for each mutation type (n = 300)
Mutation type, n (%)
C-terminal 27 (9.0)
Early truncating 21 (7.0)











Table 2 Number (%) for each mutation type and medical









C-terminal 11 (9.9) 8 (6.6) 19 (8.2)
Early truncating 7 (6.3) 6 (4.9) 13 (5.6)
Large deletion 6 (5.4) 5 (4.1) 11 (4.7)
p.Arg106Trp 4 (3.6) 6 (4.9) 10 (4.3)
p.Arg133Cys 10 (9.0) 7 (5.7) 17 (7.3)
p.Arg168*c 12 (10.8) 9 (7.4) 21 (9.0)
p.Arg255* 9 (8.1) 10 (8.2) 19 (8.2)
p.Arg270* 9 (8.1) 8 (6.6) 17 (7.3)
p.Arg294* 9 (8.1) 7 (5.7) 16 (6.9)
p.Arg306Cys 6 (5.4) 6 (4.9) 12 (5.2)
p.Thr158Met 12 (10.8) 4 (3.3) 16 (6.9)
Other 16 (14.4) 46 (37.7) 62 (26.6)
Total 111d 122e 233
Medical conditions,
n/Nb (%)
Seizures 64/144 (44.4) 122/267 (45.7) 186/411 (45.3)
Unable to walk 70/150 (46.7) 97/272 (35.7) 167/422 (39.6)
Scoliosis 122/150 (81.3) 237/270 (87.8) 359/420 (85.5)
Constipation 111/146 (76.0) 221/255 (86.7) 332/401 (82.8)
Bloating 85/147 (57.8) 121/244 (49.6) 206/391 (52.7)
Gallbladder problems 3/144 (2.1) 17/233 (7.3) 20/377 (5.3)
Gastro-oesophageal
reflux diseases
22/144 (15.3) - 22/144 (15.3)
Gastrostomy 41/150 (27.3) - 41/150 (27.3)
Anderson et al. Orphanet Journal of Rare Diseases 2014, 9:87 Page 4 of 9
http://www.ojrd.com/content/9/1/87171/423), Australia (38.3%, 162/423), Canada (5.9%, 25/
423) and the UK (5.7%, 24/423). Age at the time of data
collection ranged from 18.0 to 54.3 years (median 24.9
years, IQR 21.5-30.7 years). Over two thirds of the women
(71.2%, 301/423) were living in their parental home or
with other family members and 29% (122/423) were being
cared for in facilities such as group homes and other insti-
tutions. The characteristics of the women are shown in
Table 2.
Epilepsy
Almost two-thirds (64.0%, 263/411) of the women were
taking anti-epileptic medications at the time of data col-



























































Figure 2 Risk of death during the observation period in the
Australian cohort (n = 396) by common mutation groups in
comparison to the p.Arg133Cys mutation group. The error bars
denote 95% confidence intervals. CT, C-terminal deletion; ET, early
truncating; LD, large deletion; Neg/Unk, mutation negative or unknown.
Altered breathing patterns 97/146 (66.4) - 97/146 (66.4)
Sleep disturbances 92/142 (64.8) 154/249 (61.9) 246/391 (62.9)
aAustralian Rett Syndrome Study; bthe denominator is different for each
medical condition because of some families did not compete all questionnaire
sections; c*stop codon; dnegative or unknown mutation (n = 39); enegative or
unknown mutation (n = 151).seizures. Of those receiving anti-epileptic medication,
seizures were completely controlled in 38.0% (100/263),
partially controlled in 25.9% (68/263), and were classified
as drug resistant in 36.1% (95/263). A small proportion
(5.6%, 23/411) was not taking anti-epileptic medication
despite some level of seizure activity and 13.1% (54/411)
who had previously been diagnosed with epilepsy, were
currently seizure free. Some families reported a reduction
in severity or the number of seizures with increasing age
while others reported increased seizure activity. The
p.Thr158Met mutation group had the highest odds of
individuals having active epilepsy (OR 2.77, 95% CI 0.66,
11.67) (Figure 3). There were no significant differences in









































































Figure 3 Influence of mutation type, adjusted for age, on
selected health conditions. The error bars denote 95% confidence
intervals. Seizure (n = 411) was defined as having active epilepsy.
Walking (n = 422) was defined as able to walk with or without
assistance. Scoliosis (n = 420) was defined as ever had scoliosis.
Breathing problems (n = 146) were defined as having a breathing
problem including breath holding and hyperventilation. Sleep
problems (n = 391) were defined as having sleep disturbances.
CT, C-terminal deletion; ET, early truncating; LD, large deletion;
Neg/Unk, mutation negative or unknown.
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Many of the women continued to walk independently
(17.8%, 75/422) or with a little (22.5%, 95/422) or moder-
ate amounts of assistance (20.1%, 85/422). Slightly fewer
than half (39.6%, 167/422) were unable to walk at all at
the time of data collection. Those with a large deletion
(OR 0.11, 95% CI 0.02, 0.65), or a mutation that resulted
in early truncation of the protein (e.g. p.Gly269fs) (OR 0.21,
95% CI 0.04, 1.03) appeared to be more severely affected
when compared to those with the p.Arg133Cys mutation
(Figure 3).
Scoliosis
Scoliosis had developed in the majority (85.5% 359/420).
The proportion of women who could not walk was greaterin those with scoliosis (45.3%, 162/358), in comparison to
those with no spinal curvature (8.2%, 5/61). Across muta-
tion types the odds of having scoliosis was lowest in
women with the p.Arg294* mutation (OR 0.24, 95% CI
0.05, 1.10) and highest with a large deletion (OR 3.34, 95%
CI 0.32, 35.00) (Figure 3). Information on scoliosis treat-
ment was provided by 337 of the families whose daughter
had scoliosis and in 40.0% (135/337) had undergone spinal
fusion, mostly between the ages of 11 and 16 years.
Growth and gastrointestinal disorders
Information on body weight, method of feeding and pres-
ence of reflux was only available for cases ascertained from
the ARSD. The mean weight-for-age z-score was -3.04
(SD 3.39). The majority of women (52.8%, 65/123) were
underweight (z-score ≤ -2.0) including some (8/65) who
were markedly underweight (z-score ≤ -10). Slightly fewer
than half (46.3%, 57/123) were in the normal weight range
and one was overweight (z-score ≥ 2.0). Weight-for-age
z-scores were lowest in those with large deletions (Pre-
dicted value -5.25, 95% CI -8.64, -1.86) and those with
p.Arg106Trp (Predicted value -5.18, 95% CI -8.59, -1.77)
mutations and highest in those with C-terminal mutations
(Predicted value -1.32, 95% CI -3.58, 0.93) (Figure 4).
Also for the Australian cohort, 27.3% (41/150) had had
a gastrostomy feeding tube inserted to: improve food/
fluid intake; prevent aspiration; or to provide relief from
bloating. Almost half (46.2%, 18/39) of those receiving
nutrition through gastrostomy also had some oral intake,
15.4% (6/39) had all food orally and 38.5% (15/39) had
all food/fluid intake by gastrostomy. Four women had
had a gastrostomy for a short period during childhood
and were now feeding orally.
Reflux was reported for 15.3% (22/144) of women in the
Australian cohort. For the combined Australian and Inter-
Rett cohorts, constipation was highly prevalent (82.8%,
332/401), and many were experiencing bloating (52.7%,
206/391). Biliary dyskinesia, inflammation or infection of
the gallbladder was reported for 20 women (5.3%, 20/377)
and of these 13 had undergone gallbladder surgery.
Breathing patterns
Information on breathing patterns was available for the
Australian cohort. Abnormal breathing patterns were re-
ported for two thirds of women (66.4%, 97/146) including
74.2% (72/97) who hyperventilated and 88.7% (86/97)
with breath-holding or apnoeic episodes. Within this group,
62.9% (61/97) both hyperventilated and breath-held. These
breathing patterns varied little across mutation types
(Figure 3).
Sleep disturbances, mood and anxiety
Sleep disturbances were common (62.9%, 246/391) and








































































Figure 4 Age and mutation type adjusted predicted scores of
mood and anxiety and estimated weight-for-age z-scores. The
error bars denote 95% confidence intervals. The RSBQ mood score
ranges from 0 to 16 (n = 137) and the anxiety score ranges from 0
to 8 (n = 137). Higher scores represent higher frequency of adverse
behavioural events. CT, C-terminal deletion; ET, early truncating; LD,
large deletion; Neg/Unk, mutation negative or unknown.
Table 3 Other health conditions reported (n = 320)
Medical condition, n (%)
Pneumonia 55 (17.2)
Urinary tract infection, pyelonephritis, bladder infection 48 (15.0)




Respiratory illness 13 (4.1)
Heel cord, foot surgery 12 (3.7)
Kidney stone 5 (1.6)
Insulin resistance 5 (1.6)
Polycystic ovaries/ovarian cyst 4 (1.3)
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(18/136), occasionally for 20.6% (28/136) and not at all for
66.2% (90/136) of ARSD women. In comparison to
p.Arg133Cys, sleep disturbance was more prevalent in
those with p.Arg294* (OR 1.39, 95% CI 0.30, 6.55) and less
common in those with p.Arg106Trp mutations (OR 0.29,
95% CI 0.06, 1.52) and those with p.Arg255* (OR 0.41
95% CI 0.09, 1.79) (Figure 3).
Families participating in the InterRett study reported
that 46.0% (109/237) experienced screaming spells during
the day. Otherwise, information on mood and anxiety was
only available for those in the ARSD (n = 137). Informa-
tion pertinent to mood and behaviour, obtained using the
RSBQ, indicated that adverse behaviour such as screaming
spells and irritability occurred often (RSBQ score >=11) in
19% of women, occasionally (RSBQ score 6-10) in 41%
and rarely (RSBQ score <=5) in the remainder (40%). Anx-
iety, as determined by response to four related RSBQ
questions was experienced often (RSBQ score >=7) for
11%, occasionally (RSBQ score 3-6) for 58% and rarely if
ever (RSBQ score <=2) for 31%.
The average score for mood was 6.86 (SD 4.07) out of a
possible total of 16. After adjusting for age group, pre-
dicted mood scores above the average (indicating difficult
behaviour) were observed for mutation groups consideredto have a milder phenotype, p.Arg133Cys (Predicted score
9.07, 95% CI 6.36, 11.78) and p.Arg294* (Predicted score
8.76, 95% CI 6.09, 11.44) and also those with a large
deletion (Predicted score 8.95, 95% CI 5.35, 12.56) who
generally have a more severe overall phenotype (Figure 4).
Individuals within the 26-30 years age group were likely to
have a slightly higher mood scores (Predicted score 8.54,
95% CI 7.00, 10.09) compared to younger women (Predic-
ted score 6.50, 95% CI 5.59, 7.41) and those over 30 years
of age (Predicted score 6.16, 95% CI 4.60, 7.72) after
adjusting for mutation type.
The average score for anxiety was 3.66 (SD 2.14) out
of a possible total of 8. In comparison to those with
p.Arg133Cys mutations (Predicted score 5.09, 95% CI
3.69, 6.48), women with p.Thr158Met had reduced anx-
iety (Predicted score 2.45, 95% CI 1.14, 3.76) as did those
with p.Arg168* mutations (Predicted score 3.23, 95% CI
1.97, 4.49) after adjusting for age group (Figure 4). As with
mood, those aged 26-30 years were likely to experience
slightly more episodes of anxious behaviour (Predicted
score 4.21, 95% CI 3.41.5.01) compared to younger women
(Predicted score 3.62, 95% CI 3.15, 4.08) or those over 30
years (Predicted score 3.20, 95% CI 2.40, 4.01) after adjust-
ing for mutation type.
Other health issues
Responses to questions regarding hospitalisations, in-
vestigations and treatments for health issues other
than those normally associated with Rett syndrome re-
vealed 11 conditions reported for at least 4 individuals
(Table 3). Of these, urinary tract infections and respiratory
conditions, including pneumonia, were the most com-
monly reported.
Discussion
Using a population-based cohort we have shown that
current survival to the age of 20 years is 77.6% with 59.8%
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and older we found that epilepsy, breathing and sleep
problems persisted, low weight and gastrointestinal issues
were prevalent and although most have scoliosis loss of
walking is not inevitable. The influence of genotype, while
moderate, is in agreement with previous findings.
A major strength of this study is the rich data sources
available for analyses. Our population-based ARSD with
follow-up of individuals up to 20 years was coupled with
up-to-date death information has allowed us to make an
accurate estimate of survival in Rett syndrome. Our
cross-sectional analysis of a large multi-country study
population, over half of whom have a confirmed muta-
tion in the MECP2 gene has allowed us to more fully
investigate the clinical profile, and influence of genotype,
in ageing women. Limitations of this study include lack
of representation of older women not living in the par-
ental home in the international community since, unlike
those who live in their parental home, their family mem-
bers would be less likely to be active participants in
online initiatives such as the InterRett database. Despite
the survival analysis being undertaken on Australian
population-based data collected over 20 years the capacity
to detect differences in mortality risk across mutation
groups was limited by the small number of deaths within
specific mutation groups.
Importantly, we can now report survival in the ARSD
cohort of slightly less than 60% at 38 years of age
although the current estimate of survival to 25 years
(71.5%) is lower compared to our 2006 analysis (77.8%)
[23]. Death was most commonly caused by respiratory
illnesses. Increased ascertainment and follow-up of indi-
viduals in the more recent analyses likely explains the
difference in the survival estimate over time. A higher
estimate of survival to 25 years (~80%) was reported for
a cohort of US and Canadian females (n = 1,907) [13].
The authors of this study reported that many known
individuals who had been identified through the family
association were not included in their analysis due to
failure to make contact (52%, n = 1,555) and it is likely
that individuals who have not registered with the family
association or clinics also exist within the US and
Canadian populations. The survival estimate is likely
over-estimated because it is quite plausible that the pro-
portion of deceased compared to living cases would have
been higher in the group whose families were not able to
be contacted in comparison to the group whose families
were able to be contacted and on whose data the analysis
was based. As recommended by the authors of the study,
a population-based national registry, similar to that in
Australia, with links to national death registry and other
pertinent data sources might be advantageous, as mortal-
ity in such cohort will yield more precise survival rates as
case numbers and periods of follow-up increase over time.Compared to those with the p.Arg133Cys mutation,
the risk of death was high in those with a p.Arg270* mu-
tation consistent with our previous findings [24]. Our
new findings indicate that survival in those with the p.
Arg106Trp mutation or large deletion is similar to that
of the p.Arg270* group and that those with p.Arg255*
mutations demonstrate better survival. A proportion of
those who were older had not been tested for a MECP2
mutation because of its relative recent availability and
some families do not now want to revisit diagnostic pro-
cesses. Nevertheless, genetic testing for women with a
clinical diagnosis of Rett syndrome has important roles
to play. Some families do value more specific diagnostic
information [25] and the data contributes to greater accu-
racy in future estimations of the effects of genotype on
phenotype including survival.
Our cross-sectional analyses used the largest sample
size to date for investigating health and wellbeing in adult-
hood. Seizures are common in Rett syndrome and not
surprisingly, almost two-thirds (263/411) of the women
continued to take anti-epileptic medications at the time of
data collection. Previous studies have reported stabilisa-
tion or improvement in epilepsy in older women [7].
While some parents in the current study noted that the
frequency or severity of seizures had diminished with age,
the majority had active seizures, and of these, a third was
considered to be refractory. An investigation of epilepsy in
the InterRett study showed similar results for those aged
17 years or older [18]. These findings indicate that
management of epilepsy remains a serious challenge
in ageing women and this picture was consistent across all
mutation types.
Over half (60%) of the study cohort had some walking
skills at the time of data collection. The proportions of
women who could walk independently, with assistance,
or not at all, were similar to that previously reported for
an Italian cohort of women and adolescents aged 14 or
more years [8]. A longitudinal study of adult women
with Rett syndrome conducted in the Netherlands [7]
indicated that age-related deterioration of gross motor
function is slow. This observation concurs with findings
from a video study which investigated general stability in
gross motor function over a 3- to 4-year period: girls
younger than 13 years with walking skills were more
likely than teenagers and women to lose the more com-
plex motor skills that enabled better negotiation of the
environment [26]. Together these findings add strength
to the thesis that loss of walking is not inevitable as
women with Rett syndrome age. It is likely, however,
that these women represent the milder range of the
severity spectrum and that those who could not walk from
an early age, being more severely affected, may have died
before reaching adolescence or adulthood. Those with
spinal curvature were less likely to be ambulant and
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The proportion of those who could walk in the
p.Arg133Cys mutation baseline group (76%) was similar
to those with a p.Arg294* mutation (81%) and signifi-
cantly better than those with large deletions (27%). Im-
proved gross motor skills for those with a p.Arg133Cys
and p.Arg294* has been previously observed in a video
study of 99 girls and women from the ARSD registry, 29
of whom were 19 years or older, possibly reflecting some
survival bias [10]. A 2008 study (n = 272) found that the
overall phenotype of those with p.Arg133Cys and p.Arg294*
mutations is mild [5] and Cuddapah et al [6] found sig-
nificant differences in ambulation, not adjusted for age,
between those with p.Arg133Cys and nine other mutation
groups (p.Thr158Met, p.Arg168*, p.Arg255*, p.Arg270*,
Deletions, Insertions, Large Deletions, Splice Sites and No
mutations). These consistent findings across and within
age groups help to provide a clearer clinical picture of
mobility outcomes in those affected by these common
mutations.
We found, as had others, that sleep disturbance [7,8]
and gastrointestinal problems [7] were highly prevalent in
older women. We recently found the rate of gall bladder
disease in a Rett syndrome population-based study to be
2.3 per 1000 person years (ie. two new cases if 100 individ-
uals are followed for 10 years) [27]. Available population-
based data on typical paediatric populations suggested a
lower prevalence than this [28,29]. Although gall bladder
disease was identified in 5% of adults in our current study
it is unclear how this compares with the general popu-
lation. We suggest that gall bladder disease should be
considered in the differential diagnosis of abdominal pain
in Rett syndrome.
Unusual breathing patterns including hyperventilation
and breath holding were highly prevalent yet there has
been a paucity of research in this area. Women with a
p.Arg255* mutation were least likely to hyperventilate
and also had a lower mortality. The influence of breath-
ing irregularities on overall health and survival is not
well understood and further research in this area is
warranted. Similarly, the frequency of respiratory type
infections indicates that these health issues may also
need to be closely monitored, including attention to up-
right postures during daytime activities and a low thresh-
old to the prescription of antibiotics.
Fortunately, behavioural difficulties and anxiety only
appeared to affect a relatively small proportion of women
although these issues would likely have a major impact on
the daily quality of life of those with Rett syndrome and
their carers. Small increases in the mood and anxiety
scores were observed for those aged 26-30 years in
comparison to the older and younger age groups. In
the Dutch cohort, behaviour was assessed using theObservational Questionnaire Elderly Residents with
Intellectual Disabilities (OOB). Based on this instru-
ment, two thirds of Dutch women showed anxiety
and during the five year study period improvements were
mainly seen in those age 30 years or more (2007-2012)
[7]. It might be expected that those with a milder pheno-
type can better communicate their feelings, however,
we observed higher predicted scores for mood and
anxiety in mutations associated with both mild and
severe phenotypes.
The change in composite health status by mutation
type over time was outside the scope of the current
study. However, a previous study of health trajectories
over time in our Australian cohort [30] found that for
most mutations, including p.Arg133Cys where health
status at a younger age was better, health status dete-
riorated over time. For a few others, which tended to be
severe mutations, health status either remained un-
changed (pArg106Trp) or improved slightly (p.Arg255*
and p.Arg168*) with age [30]. The authors of the US
longitudinal study [6] reported that severity of symptoms
increased by age for most mutation types in both cross-
sectional analysis across five age groups and longitudinal
analysis within individuals. The severity score for an
individual was determined by a protocol developed by
the authors who acknowledged that the inclusion of
some items, which cannot change with time, may have
led to an underestimation of age-related changes in their
longitudinal analyses. Given that there is considerable
variance in clinical outcomes within mutation types,
consistent ongoing follow-up of existing cohorts is re-
quired to obtain a clearer picture of mutation-specific
severity in women with Rett syndrome.
Conclusion
The data contained in this paper represents twenty years
of surveillance and highlights the consistent research
effort required to understand rare disorders. Individuals
with Rett syndrome have potential for prolonged sur-
vival with approximately 60% surviving to early middle
age. Many women continue to have some level of ambu-
lation and it is therefore critical to develop and advocate
for care plans that help to maintain and build on these
skills. Further investigation into mood and anxiety could
help to better define needs and inform care strategies.
We also recommend that the maintenance of clinical
care services for adults with Rett syndrome including
close monitoring of respiratory and gastrointestinal
function. The impact of breathing irregularities on sur-
vival is poorly understood and is an important topic
for future investigation. Ongoing monitoring of the
ARSD and other population-based cohorts has a vital
role in providing accurate estimates of survival in Rett
syndrome.
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